<DOC>
	<DOCNO>NCT00226512</DOCNO>
	<brief_summary>Multi-institutional randomized phase III trial non-myeloablative preparative regimen fludarabine busulfex without anti-lymphocyte antibody ( monoclonal humanize Campath-1H administer s.c. polyclonal rabbit anti-T lymphocyte antibody ( ATG ) , combine low dose short course cyclosporine A ( CSA ) methotrexate ( MTX ) sole agent prevention graft-vs-host disease ( GVHD ) patient acute myelogenous leukemia myelodysplastic syndrome undergo allogeneic stem cell transplantation HLA compatible donor .</brief_summary>
	<brief_title>To Determine Role Adding Campath-1H ATG Given In-vivo Addition Fludarabine Low Dose Busulfex Outcome Patients Treated With Reduced Intensity Conditioning</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Confirmed diagnosis AML MDS , low upper age limit : ) Induction failure b ) First subsequent remission c ) Untreated first relapse Patients must HLA compatible donor willing capable donate peripheral blood stem cell ( first choice ) bone marrow progenitor cell use conventional technique blood lymphocyte indicate ( HLA compatible define 5/6 6/6 match related 10/10 molecular match unrelated donor ( A , B , C , DR , DRB1 ) . Donor contraindication ( HIV seropositive confirm Western Blot , Hepatitis B antigenemia ) . Evidence bone marrow disease . Unable donate bone marrow peripheral blood due concurrent medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>